Clinical utilization of blinatumomab in Chinese monocentric patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Abstract Purpose: Blinatumomab has promising applications in treating relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, there are few studies on using blinatumomab for treating R/R B-ALL patients in China. Therefore, we evaluated the efficacy and safety of blinatumomab among Chinese R/R B-ALL patients. Methods: In total, 39 R/R B-ALL patients who received blinatumomab between October 2021 and August 2022 were selected as the study subjects. The primary endpoints include overall response rate (ORR) and complete minimal residual disease (MRD) response. Secondary endpoints included overall survival (OS) and adverse events (AEs). Results: The ORR and OS for 19 patients with less than 5% bone marrow (BM) blasts were 63.2% and 11 months (7.3–14.7), respectively. The median OS for the 20 patients was unavailable, and 17 (or 85%) had a full MRD response. Twenty-seven patients (69.2%) reported having at least 1 AE. Hematologic toxicity and infections were the most common AEs. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed on nine patients who had been remission-free for a long time. In the first month, one patient (11.1%) developed thrombotic microangiopathy associated with HSCT (TA-TMA) following transplantation. Conclusion: In R/R B-ALL patients, blinatumomab is an effective option in China.